CollPlant Biotechnologies (CLGN)
(Delayed Data from NSDQ)
$4.94 USD
-0.12 (-2.36%)
Updated Jul 16, 2024 03:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Brokerage Reports
CollPlant Biotechnologies Ltd. Sponsored ADR [CLGN]
Reports for Purchase
Showing records 41 - 52 ( 52 total )
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
2H20 Could Be Catalyst-Rich Despite COVID-19; Higher $13 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
BUY- Reports the Quarter as We Move Closer to Catalysts
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
We Expect Major Milestones in 2020 in Spite of COVID-19; Higher $11PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
Awaiting Additional Partnership Announcements; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
Pure Collagen from Tobacco, A Healthier Alternative
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
Advances in 3D Bioprinting and Dermal Filler; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
Termination of coverage
Provider: Edison Investment Research Limited
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
Farming a Better Human Collagen; Initiate With Buy and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
Enters into licensing and commercialisation agreement
Provider: Edison Investment Research Limited
Analyst: JACOBS M